AOD-9604
MetabolicAlso known as AOD9604, hGH fragment 176-191
Evidence tier
Limited published literature
16 publications over 25 years · trials not yet curated
- Researched since
- 2001
- Publications
- 16
- Mean purity
- 99.5%
- Vendors listing
- 20
Ascend Science shows the highest mean assayed purity for AOD-9604 at 99.8% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2001 — 25 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
16 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.5% across 14 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.28 pts purity across lots, mean label deviation 8.7%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
20 of 20 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
14 of 14 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is AOD-9604?
A modified fragment of the C-terminus (residues 176–191) of human growth hormone, studied for effects on fat metabolism without the growth-promoting activity of the full-length hormone.
Studied in published research for fat metabolism and weight loss.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and in human obesity trials that did not meet their primary weight-loss endpoint. PepIndex does not evaluate clinical significance and does not describe administration.
- AOD-9604 Metabolic — Current opinion in investigational drugs (London, England : 2000) (2004)
Peer-reviewed article indexed in PubMed, published in Current opinion in investigational drugs (London, England : 2000) (2004).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) (2026)
Peer-reviewed article indexed in PubMed, published in Sports medicine (Auckland, N.Z.) (2026).
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug testing and analysis (2013)
Peer-reviewed article indexed in PubMed, published in Drug testing and analysis (2013).
- Human sports drug testing by mass spectrometry — Mass spectrometry reviews (2017)
Peer-reviewed article indexed in PubMed, published in Mass spectrometry reviews (2017).
- Obesity drugs in clinical development — Current opinion in investigational drugs (London, England : 2000) (2006)
Peer-reviewed article indexed in PubMed, published in Current opinion in investigational drugs (London, England : 2000) (2006).
- Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls — Journal of pharmaceutical and biomedical analysis (2014)
Peer-reviewed article indexed in PubMed, published in Journal of pharmaceutical and biomedical analysis (2014).
- Gateways to clinical trials — Methods and findings in experimental and clinical pharmacology (2003)
Peer-reviewed article indexed in PubMed, published in Methods and findings in experimental and clinical pharmacology (2003).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 1 | 99.8% | 31.7% | |
| PeptidePlugs | 89.790% | — | 4 | 99.4% | 6.1% | |
| American PeptidesISO/IEC 17025 | 83.6100% | $12.00 (114%) | 1 | 99.7% | 10.8% | |
| Koi Peptides | 82.794% | $9.00 (86%) | 0 | — | — | |
| Protide Health | 8194% | $12.00 (114%) | 0 | — | — | |
| Northline LabsISO/IEC 17025 | 79.493% | — | 1 | 99.7% | 0.5% | |
| Good Science Bio | 79.275% | $5.00 (48%) | 0 | — | — | |
| NeuroLabs Research | 79.186% | $10.00 (95%) | 0 | — | — | |
| Ascension Peptides | 77.186% | $11.00 (105%) | 2 | 99.6% | 4.5% | |
| Licensed Peptides | 7789% | — | 1 | 99.2% | 4.6% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.8% | 13.2% | |
| Simple Peptide | 7489% | — | 1 | 99.7% | 6.8% | |
| Next Gen PeptidesISO/IEC 17025 | 73.897% | $24.00 (229%) | 1 | 99.7% | 5.0% | |
| GenX Peptides | 72.168% | $8.40 (80%) | 0 | — | — | |
| True Research Labs | 71.671% | $8.80 (84%) | 0 | — | — | |
| Mile High Compounds | 71.194% | $6.00 (57%) | 0 | — | — | |
| Biotech Peptides | 7163% | $8.00 (76%) | 0 | — | — | |
| Vertex Labs | 66.270% | $18.00 (171%) | 1 | 99.1% | 16.3% | |
| Evolve Peptides | 6567% | $11.00 (105%) | 0 | — | — | |
| Sports Technology Labs | 60.574% | $14.40 (137%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Vertex Labs | 2608190849 | Freedom Diagnostics Testing | 10 mg | 8.37 mg | 16.3% | 99.1% | Vendor-published | |
| Ascend Science | AS-AOD5-2 | Kovera Labs and/or ILS Labs | 10 mg | 6.83 mg | 31.7% | 99.8% | Vendor-published | |
| PeptidePlugs | 160-142L-DK | Freedom Diagnostics Testing | 2 mg | 1.93 mg | 3.5% | 99.2% | Vendor-published | |
| PeptidePlugs | 155-01-DK | Freedom Diagnostics Testing | 5 mg | 4.36 mg | 12.8% | 99.0% | Vendor-published | |
| Next Gen Peptides | AD05-06 | ILS Laboratories | 5 mg | 5.25 mg | 5.0% | 99.7% | Vendor-published | |
| PeptidePlugs | 144-04-DK-BL | Freedom Diagnostics Testing | 5 mg | 4.63 mg | 7.4% | 99.7% | Vendor-published | |
| Modern Aminos | BX-P-H9C4 | Analysis FreedomDiagnostics | 5 mg | 4.34 mg | 13.2% | 99.8% | Vendor-published | |
| Simple Peptide | AOD10-062026-4 | Analysis FreedomDiagnostics | 10 mg | 9.32 mg | 6.8% | 99.7% | Vendor-published | |
| Northline Labs | NLL-3713888 | Horizon Analytical | 5 mg | 4.97 mg | 0.5% | 99.7% | Vendor-published | |
| PeptidePlugs | 112-U | Freedom Diagnostics Testing | 5 mg | 5.03 mg | 0.6% | 99.8% | Vendor-published | |
| Ascension Peptides | 09-01260229 | MZ Biolabs | 5 mg | 4.56 mg | 8.8% | 99.5% | Vendor-published | |
| American Peptides | AOD5-0318 | Excellence in HPLC-MS Analysis | 5 mg | 5.54 mg | 10.8% | 99.7% | Vendor-published | |
| Licensed Peptides | 1201AOR | Vanguard Laboratory | 5 mg | 4.77 mg | 4.6% | 99.2% | Vendor-published | |
| Ascension Peptides | 09-03250428 | MZ Biolabs | 5 mg | 4.99 mg | 0.2% | 99.8% | Vendor-published |